Prentiss Smith & Co. Inc. Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Prentiss Smith & Co. Inc. decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 32.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,656 shares of the biopharmaceutical company’s stock after selling 1,779 shares during the period. Regeneron Pharmaceuticals comprises about 2.4% of Prentiss Smith & Co. Inc.’s holdings, making the stock its 19th largest holding. Prentiss Smith & Co. Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,211,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Fortitude Family Office LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $31,000. MCF Advisors LLC lifted its position in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares in the last quarter. Criterion Capital Advisors LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $37,000. Finally, Sutton Wealth Advisors Inc. lifted its position in Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 13 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on REGN shares. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 20th. Truist Financial reissued a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Barclays increased their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. UBS Group increased their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Finally, Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $977.77.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the transaction, the director now directly owns 18,282 shares in the company, valued at $17,953,838.10. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,022 shares of company stock worth $10,552,991. 8.83% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Down 1.7 %

Shares of Regeneron Pharmaceuticals stock traded down $15.86 during trading on Thursday, hitting $890.68. 574,971 shares of the stock were exchanged, compared to its average volume of 490,896. The firm’s 50-day moving average price is $950.58 and its 200 day moving average price is $893.29. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The stock has a market cap of $97.76 billion, a price-to-earnings ratio of 26.09, a price-to-earnings-growth ratio of 2.61 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the business posted $10.96 earnings per share. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.